Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Epidemiology and Access to Expert Care for the Neuronal Ceroid Lipofuscinoses (NCL)
Child Neurology and Developmental Neurology
Child Neurology and Developmental Neurology Posters (7:00 AM-5:00 PM)
035

To evaluate models of geographic burden in accessing expert care for a rare neurological disorder and possible solutions to mitigate that burden.

Most rare diseases are genetic with onset in childhood; many cause progressive neurological deterioration. One such disease is the NCLs. Access to expert care for these disorders presents challenges due to the scarcity of disease-specific expertise and potential mismatch between patient and expert location. We hypothesized that access to expertise would require substantial travel.

We investigated the distribution of NCL families using a convenience sample of data from two NCL contact registries in the US. We used ArcGIS to develop maps using zip codes from families in relation to 1) BDSRA-designated centers of excellence (known experts), 2) cerliponase alfa infusion centers (experts in CLN2 disease), and 3) pediatric neurology residency programs (possible NCL experts). We used spatial analysis to determine the distance and driving time to specialists using these 3 models.

Based on 685 cases, 7% of individuals lived within a 3-hour drive of a center of excellence, 59% lived within a 3-hour drive of a cerliponase alfa infusion center, and 88% lived within a 3-hour drive of a pediatric neurology training program. The median driving time to a center of excellence was 8 hours, to an infusion center was 1.8 hours, and to a pediatric neurology program was 1.2 hours. There were no obvious clusters of cases within the United States. The geographic density of NCL families appeared to parallel the US population distribution density.

We created 3 models exploring access to potential expert care. Our sampling method likely missed cases and other methods such as snowball sampling may yield more robust results.  With the increasing development of therapeutics for the NCLs and other rare diseases, improved models for convenient and sustainable access to care are essential.
Authors/Disclosures
Margaux C. Masten, Undergraduate
PRESENTER
The institution of Miss Masten has received research support from Âé¶¹´«Ã½Ó³»­. The institution of Miss Masten has received research support from Neurogene. The institution of Miss Masten has received research support from Amicus. The institution of Miss Masten has received research support from Beyond Batten Disease Foundation. The institution of Miss Masten has received research support from NIH.
No disclosure on file
Erika F. Augustine, MD, FÂé¶¹´«Ã½Ó³»­ (Kennedy Krieger Institute) The institution of Dr. Augustine has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Latus Bio. Dr. Augustine has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for American Board of Psychiatry and Neurology. Dr. Augustine has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Annals of Neurology. The institution of Dr. Augustine has received research support from NIH. The institution of Dr. Augustine has received research support from Beyond Batten Disease Foundation. Dr. Augustine has received publishing royalties from a publication relating to health care. Dr. Augustine has a non-compensated relationship as a Member, Board of Directors with American Brain Foundation that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities. Dr. Augustine has a non-compensated relationship as a Scientific Advisor with ARIA that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities.
Jonathan W. Mink, MD, PhD, FÂé¶¹´«Ã½Ó³»­ The institution of Dr. Mink has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amicus. The institution of Dr. Mink has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurogene. Dr. Mink has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TEVA. Dr. Mink has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC Therapeutics. Dr. Mink has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Applied Therapeutics. Dr. Mink has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Âé¶¹´«Ã½Ó³»­. The institution of Dr. Mink has received research support from Neurogene. The institution of Dr. Mink has received research support from NIH. Dr. Mink has received publishing royalties from a publication relating to health care. Dr. Mink has received personal compensation in the range of $500-$4,999 for serving as a Member, Study Section with NINDS.